RecruitingPhase 2NCT06613880

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

Studying Aplastic Anemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator
Jun Shi, PhD
Institute of Hematology & Blood Diseases Hospital, China
Intervention
standard IST combined with Romiplostim N01(drug)
Enrollment
48 enrolled
Eligibility
12 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06613880 on ClinicalTrials.gov

Other trials for Aplastic Anemia

Additional recruiting or active studies for the same condition.

See all trials for Aplastic Anemia

← Back to all trials